Icatibant

Раствор By prescription

A bradykinin B2-receptor blocker drug, an anti-allergic drug used for symptomatic therapy of acute attacks of hereditary angioedema in adults with C1 esterase inhibitor deficiency.

Icatibant

Indications

Icatibant is indicated for the symptomatic treatment of acute attacks of hereditary angioedema (due to C1 esterase inhibitor deficiency) in adults, adolescents and children aged 2 years and older.

Contraindications

Hypersensitivity to the drug components (active substance and excipients), concomitant use of angiotensin-converting enzyme inhibitors, children under 18 years of age (efficacy and safety of use have not been established).

Usage

Icatibant should be administered under the supervision of a qualified health care professional. The decision on the possibility of self-administration of Icatibant by the patient or his/her carer is made by a physician experienced in the diagnosis and treatment of HAE. Patients with clinical manifestations of laryngeal oedema should be urgently hospitalised and should be under medical supervision until the HAE attack is completely resolved. The syringe containing Icatibant is intended for single use only.

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Drugs in the category Allergology

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.